DNA Damage

Shop By

Items 101-150 of 444

Page
per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Citations
  1. DNA-PK inhibitor

    Compound 401 is a cell-permeable pyrimido-isoquinolinone compound that acts as a potent, reversible, and ATP-competitive inhibitor of DNA-PK (IC50 = 280 nM) with ~19-fold selectivity over mTOR (IC50 = 5.3 μM).
  2. Topoisomerase II inhibitor

    Flumequine is a synthetic chemotherapeutic antibiotic which affecting mammalian chromosome and DNA unwinding at the level of gyrase/topoisomerases.
  3. HDAC inhibitor

    Romidepsin strongly inhibits HDAC1 and HDAC2 with IC5N/A of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC5N/A 25 nM and 79N/A nM, respectively.
  4. HDAC6 inhibitor

    ACY-1215 selectively targets and binds to HDAC6, thereby disrupting the Hsp90 protein chaperone system through hyperacetylation of Hsp90 and preventing the subsequent aggresomal protein degradation.
  5. HDAC Inhibitor

    CI-994 is a histone deacetylase (HDAC) inhibitor and induces histone hyperacetylation in living cells.
  6. Topoisomerase

    (S)-10-Hydroxycamptothecin is a camptothecin derivative that inhibits DNA topoisomerase by enacting strand breaks in chromosomal DNA and inducing apoptosis.
  7. DNA topoisomerase Inhibitor

    SN 38 is the active metabolite of irinotecan (an analog of camptothecin - a topoisomerase I inhibitor).
  8. HDAC inhibitor

    Remetinostat (SHP-141) is a hydroxamic acid-based inhibitor of histone deacetylase enzymes (HDAC) which is under development for the treatment of cutaneous T-cell lymphoma.
  9. HDAC inhibitor

    CRA-026440 is a potent, broad-spectrum HDAC inhibitor.
  10. sirtuin inhibitor

    Sirtinol is a cell-permeable, specific inhibitor of sirtuin NAD-dependant histone deacetylases. It is a specific SIRT1 and SIRT2 inhibitor with IC50 of 131 μM and 38 μM in cell-free assays, respectively.
  11. HDAC inhibitor

    CXD101 is a class I-selective HDAC inhibitor (HDAC1 (IC50, 63 nM), HDAC2 (IC50, 570 nM), HDAC3 (IC50, 550 nM). CXD101 has no activity against HDAC class II.
  12. Sirt1/Sirt2 inhibitor

    Salermide is an inhibitor of Sirt1 and Sirt2; can cause strong cancer-specific apoptotic cell death.
  13. eIF4E-eIF4G interaction inhibitor

    4E2RCat is an inhibitor of eIF4E-eIF4G interaction with an IC50 of 13.5 μM.
  14. HCV NS5B polymerase inhibitor

    VCH-916 is a novel nonnucleoside HCV NS5B polymerase inhibitor.
  15. SIRT1/SIRT2 inhibitor

    Cambinol is a SIRT1 and SIRT2 inhibitor with IC50 values of 56 and 59 μM, respectively.
  16. PARP Inhibitor

    AZD2461 is a novel and potent PARP inhibitor with lower affinity to P-glycoprotein.
  17. Topoisomerase inhibitor

    Epirubicin is a cell-permeable antitumor antibiotic. A stereoisomer of Doxorubicin that exhibits reduced cardiotoxicity. Epirubicin?€?s antitumor actions are mediated by targeting and inhibiting Topo II (topoisomerase II).
  18. HDAC6 inhibitor

    ACY-775 is a potent and selective inhibitor of the of histone deacetylase 6 (HDAC6) with an IC50 of 7.5?nM.
  19. IRE1α inhibitor

    MKC3946 is a potent and soluble IRE1α inhibitor, used for cancer research.
  20. HDAC1/HDAC2 inhibitor

    BRD-6929 (Cpd-60) is a brain-penetrant, selective inhibitor of HDAC1 and HDAC2 (IC50=?1 and 8 nM), extracted from patent US2018360927.
  21. IRE1α RNase kinase inhibitor

    KIRA6 is an advanced small-molecule IRE1α RNase kinase inhibitor with an IC50 of 0.6 ?M. KIRA6 can trigger an apoptotic response.
  22. SIRT1 inhibitor

    Inauhzin is a potent SIRT inhibitor, which effectively reactivates p53 by inhibiting SIRT1 activity, promotes p53-dependent apoptosis of human cancer cells without causing apparently genotoxic stress.
  23. Topoisomerase I inhibitor

    9-Aminocamptothecin is a topoisomerase I inhibitor with potent anticancer activity.
  24. HDAC inhibitor

    Resminostat, also known as RAS2410, is a potent inhibitor of histone deacetylase (HDAC) classes I and II. It binds to and inhibits HDACs leading to an accumulation of highly acetylated histones.
  25. topoisomerase II inhibitor

    Ametantrone (AM) is a synthetic 9,10-anthracenedione bearing two (hydroxyethylamino)ethylamino residues at positions 1 and 4 along with other anthraquinones and anthracyclines.
  26. HDAC4 inhibitor

    Tasquinimod is an orally active antiangiogenic agent by allosterically inhibiting HDAC4 signalling.
  27. Topoisomerase II inhibitor

    Amrubicin is a synthetic anthracycline antibiotic. It inhibits DNA topoisomerase II. Antineoplastic.
  28. PARP inhibitor

    PJ 34 hydrochloride is a potent inhibitor of poly(ADP-ribose) polymerase (PARP) (EC50 = 20 nM).
  29. DHFR inhibitor

    Pemetrexed is a novel antifolate with multiple targets
  30. eIF2α dephosphorylation inhibitor

    Salubrinal is a cell-permeable, selective inhibitor of cellular phosphatase complexes that dephosphorylate eukaryotic translation initiation factor 2 subunit α (eIF2α). Protects cells from endoplasmic reticulum stress-induced apoptosis (EC50 ~ 15 μM).
  31. HDAC inhibitor

    Scriptaid is an HDAC inhibitor (histone deacetylase).
  32. HDAC inhibitor

    Apicidin is a a potent histone deacetylases (HDAC) inhibitor with potential anticancer activity.
  33. PARP2 inhibitor

    UPF 1069 is a selective poly(ADP-ribose) polymerase (PARP) 2 inhibitor (IC50 values are 0.3 and 8.0 μM for PARP-2 and PARP-1 respectively).
  34. DNA-PK inhibitor

    NU7026 is a novel DNA-dependent protein kinase inhibitor that potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia.
  35. HDAC6 inhibitor

    ACY-241 is a new, selective and orally available inhibitor of HDAC6.
  36. topoisomerase I inhibitor

    Gimatecan is an orally bioavailable, semi-synthetic lipophilic analogue of camptothecin, a quinoline alkaloid extracted from the Asian tree Camptotheca acuminate, with potential antineoplastic and antiangiogenic activities.
  37. SIRT2 inhibitor

    AK-7 is a cell- and brain-permeable inhibitor of SIRT2 (IC50 = 15.5 μM).
  38. HDAC6 inhibitor

    BRD9757 is a highly potent and selective HDAC6 inhibitor with an IC50 of 30 nM toward HDAC6.
  39. eIF4A3 inhibitor

    eIF4A3-IN-1 (compound 53a) is a selective eukaryotic initiation factor 4A3 (eIF4A3) inhibitor (IC50=0.26 μM; Kd=0.043 μM).
  40. Topoisomerase II inhibitor

    Pixantrone is a topoisomerase II inhibitor and DNA intercalator, with anti-tumor activity.
  41. DNA topoisomerase II inhibitor

    Beta-Lapachone is a selective DNA topoisomerase I inhibitor, exhibiting no inhibitory activities against DNA topoisomerase II or ligase.
  42. HCV Polymerase Inhibitor

    Setrobuvir (ANA-598) is a direct-acting antiviral or DAA, is a non-nucleoside inhibitor of the HCV RNA polymerase
  43. HDAC inhibitor

    RG2833 ( is a brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3.
  44. ATM/ATR inhibitor

    CGK733 is a selective inhibitor of ATR and ATM kinases. Induces cell death in prematurely senescent breast cancer cells.
  45. ATR kinase inhibitor

    AZ20 is a potent and selective inhibitor of ATR with an IC50 value of 5 nM.
  46. topoisomerase 1 inhibitor

    Genz-644282 is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity.
  47. HDAC3 inhibitor

    RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM, exhibits > 200-fold selectivity over other HDAC.
  48. DNA-PK inhibitor

    KU0060648 is a potent and selective inhibitor of DNA-dependent protein kinase (DNA-PK), (IC50 = 8.6 nM); with 20-1000 fold selectivity for DNA-PK over other PIKKs and a panel of 60 kinases. KU-0060648 enhances HDR efficiency and attenuates NHEJ frequency.
  49. ERCC1-XPF inhibitor

    NSC16168 is a specific inhibitor of ERCC1-XPF, with an IC50 value of 0.42 μM. NSC16168 inhibits DNA repair and potentiates CDDP efficacy in cancer.
  50. Thymidylate synthase inhibitor

    Nolatrexed Dihydrochloride is an antifolate thymidylate synthase inhibitor.

Items 101-150 of 444

Page
per page
Set Descending Direction